Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets
arcticnovartis
Thu, 11/20/2025 – 07:04
Read more about Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth…
Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets
arcticnovartis
Thu, 11/20/2025 – 07:04
Read more about Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth…
Novartis announces plans to build flagship manufacturing hub in North Carolina
arcticnovartis
Wed, 11/19/2025 – 18:34
Read more about Novartis announces plans to build flagship manufacturing hub in North Carolina
Expansion repres…
Novartis announces plans to build flagship manufacturing hub in North Carolina
arcticnovartis
Wed, 11/19/2025 – 18:34
Read more about Novartis announces plans to build flagship manufacturing hub in North Carolina
Expansion repres…
Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials
arcticnovartis
Mon, 11/17/2025 – 11:20
Read more about Novartis ianalumab first drug to reduce disease activity and patient burden in…
Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials
arcticnovartis
Mon, 11/17/2025 – 11:20
Read more about Novartis ianalumab first drug to reduce disease activity and patient burden in…
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline
arcticnovartis
Mon, 11/17/2025 – 11:20
Read more about New Novartis data at ASN Kidney Week and AHA Scientific Sessions demon…
Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan
arcticnovartis
Mon, 11/17/2025 – 11:20
Read more about Novartis opens new radioligand therapy manufacturing facility in California as par…
Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance
arcticnovartis
Mon, 11/17/2025 – 11:20
Read more about Novartis Phase III trial for next-gener…
Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance
arcticnovartis
Mon, 11/17/2025 – 11:20
Read more about Novartis Phase III trial for next-gener…
